GlassScriptPhysician profile
Rashida K Rahman
NPI 1982631115
$5,256.12
in general payments reported to CMS, 2019-2025
33 companies · $1,304 in 2025
The $1,304 reported for 2025 was more than what 83% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $61.20 · 2021: $580 · 2022: $876 · 2023: $997 · 2024: $1,084 · 2025: $1,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,119 · Education: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,119.18 |
| Education | $264.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $558.94 | 2019-2025 | Veltassa |
| Novartis Pharmaceuticals Corporation | $361.57 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $349.56 | 2020-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $316.76 | 2021-2025 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $288.62 | 2019-2023 | Rayaldee |
| Ani Pharmaceuticals, INC. | $285.76 | 2022-2025 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $273.98 | 2021-2024 | |
| Ardelyx, INC. | $261.28 | 2023-2025 | Ibsrela |
| Akebia Therapeutics INC | $258.36 | 2019-2025 | Vafseo, Auryxia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.92 | 2023-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $235.93 | 2022-2025 | Velphoro, Velphoro |
| Travere Therapeutics, INC. | $213.84 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $189.35 | 2022-2025 | Lupkynis |
| Novo Nordisk INC | $176.01 | 2024-2025 | Wegovy |
| Glaxosmithkline, LLC. | $155.43 | 2022-2025 | Benlysta, Jesduvroq |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $147.75 | 2021-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $142.40 | 2019-2025 | Jynarque |
| Medtronic, INC. | $136.29 | 2021 | |
| Xeris Pharmaceuticals, INC. | $111.72 | 2021-2025 | Keveyis |
| Alexion Pharmaceuticals, INC. | $100.72 | 2021-2023 | Ultomiris |
| Amgen INC. | $88.82 | 2019-2025 | Tavneos |
| Mallinckrodt Enterprises LLC | $67.34 | 2019 | |
| Calliditas Therapeutics US INC. | $62.98 | 2024-2025 | Tarpeyo |
| Lilly USA, LLC | $49.50 | 2024 | Jardiance |
| Daiichi Sankyo INC. | $38.02 | 2019 | |
| Scpharmaceuticals INC. | $33.48 | 2025 | |
| Genentech USA, INC. | $26.75 | 2025 | Gazyva |
| Genzyme Corporation | $24.80 | 2021 | |
| Kyowa Kirin, INC. | $21.11 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $19.28 | 2022 | |
| Apellis Pharmaceuticals, INC. | $18.85 | 2025 | Empaveli |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rashida Rahman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.